148.55USD+0.33%Mkt Cap: 8.38B $P/E: 165.061d ago
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fib…
Industry Peers
Medical Instruments & Supplies$142.49BUSDP/E 48.8
$84.67BUSDP/E 34.0
$73.25BUSDP/E 36.1
$44.07BUSDP/E 27.9
$31.69BUSDP/E 42.2
$29.41BUSDP/E 19.6
$25.61BUSDP/E 48.5
$19.82BUSDP/E 67.9
$18.23BUSDP/E 44.9
$18.54BUSDP/E 105.1
$14.74BUSDP/E 83.6
$13.59BUSDP/E 44.2
$14.26BUSDP/E 61.9
$14.15BUSDP/E 10.0
$12.78BUSDP/E 30.0
$12.06BUSD
$8.60BUSDP/E 23.1
$7.69BUSD
$5.63BUSDP/E 23.0
$5.99BUSDP/E 1931.7
$4.53BUSDP/E 30.5
$4.51BUSDP/E 32.6
$4.46BUSD
$4.39BUSDP/E 65.8
$4.03BUSDP/E 40.3
$4.05BUSDP/E 87.2
$3.67BUSDP/E 16.5
$3.32BUSDP/E 21.4
$3.39BUSDP/E 2759.0
$2.85BUSDP/E 21.9
$2.63BUSD
$2.77BUSD
$2.35BUSDP/E 37.9
$1.95BUSDP/E 36.0
$1.89BUSD
$1.80BUSD
$1.48BUSD
$1.44BUSD
$1.29BUSDP/E 74.9
$1.41BUSD
$1.23BUSD
$1.09BUSD
$752.64MUSDP/E 16.0
$811.83MUSD
$756.96MUSDP/E 14.8
$671.62MUSDP/E 39.2
$660.94MUSDP/E 55.9
$584.44MUSD
$360.76MUSDP/E 21.2
$354.68MUSDP/E 17.1
$272.64MUSD
$245.88MUSDP/E 13.6
$232.03MUSDP/E 422.0
$211.00MUSDP/E 35.6
$228.42MUSDP/E 21.2
$198.25MUSDP/E 23.8
$198.75MUSDP/E 1.8
$194.76MUSD
$188.63MUSDP/E 16.3
$160.12MUSD
$164.06MUSD
$123.68MUSDP/E 39.3
$115.11MUSD
$120.22MUSD
$107.50MUSD
$61.36MUSDP/E 6.4
$59.94MUSD
$48.70MUSD
$40.82MUSDP/E 53.7
$41.23MUSDP/E 41.0
$37.15MUSD
$32.43MUSD
$26.84MUSD
$25.35MUSDP/E 176.7
$20.69MUSD
$18.82MUSD
$14.75MUSD
$14.58MUSD
$13.43MUSD
$9.21MUSD
$7.52MUSDP/E 12.9
$7.46MUSD
$5.06MUSD
$4.00MUSD
$465.9KUSD
$138.6KUSD
Indicators:|
| Headline | Source | Time |
|---|---|---|
Today | ||
 Repligen (RGEN) Stock Looks Fairly Valued On Cash Flow But Fully Priced On Sales Repligen stock is coming off a mixed five year stretch, with the share price lower over that window even as more recent returns have turned positive. The valuation signals now point to a stock that is not clearly cheap, with the Discounted Cash Flow (DCF) intrinsic value estimate sitting close to the current market price while traditional multiples lean expensive. Repligen shares are down 27.9% over five years, which puts the current valuation debate in the context of a long period where... | ||
This week | ||
 Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. | ||
Older | ||